Insys Therapeutics, Inc. (NASDAQ:INSY) has been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $9.67.

INSY has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. TheStreet downgraded shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. BidaskClub cut shares of Insys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Royal Bank Of Canada reissued an “outperform” rating and issued a $14.00 price objective on shares of Insys Therapeutics in a research note on Wednesday, October 11th. Finally, Oppenheimer restated a “hold” rating on shares of Insys Therapeutics in a report on Sunday, November 12th.

Insys Therapeutics (NASDAQ INSY) opened at $5.24 on Thursday. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02.

A number of large investors have recently added to or reduced their stakes in INSY. Dynamic Technology Lab Private Ltd acquired a new position in Insys Therapeutics during the third quarter worth about $119,000. Janney Montgomery Scott LLC acquired a new position in Insys Therapeutics during the third quarter worth about $135,000. SG Americas Securities LLC acquired a new position in Insys Therapeutics during the second quarter worth about $138,000. Voya Investment Management LLC purchased a new position in Insys Therapeutics in the 2nd quarter worth about $149,000. Finally, BNP Paribas Arbitrage SA increased its stake in Insys Therapeutics by 213.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock worth $166,000 after purchasing an additional 8,940 shares in the last quarter. 25.62% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://theolympiareport.com/2017/12/07/insys-therapeutics-inc-insy-given-consensus-rating-of-hold-by-brokerages.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.